Physician profile
Rumi Khan
NPI 1184676926
$5,351.23
in general payments reported to CMS, 2019-2025
33 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $216 · 2021: $273 · 2022: $229 · 2023: $443 · 2024: $1,100 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,229.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $976.81 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $765.80 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $475.89 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $311.76 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Electromed, INC. | $255.59 | 2019-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $253.26 | 2024-2025 | Glassia, Cuvitru |
| Sunovion Pharmaceuticals INC. | $230.22 | 2019 | |
| Mylan Specialty L.P. | $207.90 | 2019-2024 | Yupelri |
| Insmed, INC. | $175.33 | 2023-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $157.58 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Verona Pharma, INC. | $155.50 | 2025 | Ohtuvayre |
| Medtronic, INC. | $148.15 | 2022 | |
| Grifols USA, LLC | $133.30 | 2020-2025 | Prolastin-C Liquid |
| Philips North America LLC | $125.49 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Genentech USA, INC. | $122.87 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $115.20 | 2019-2025 | |
| United Therapeutics Corporation | $110.10 | 2023-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $102.60 | 2023-2025 | Tezspire |
| Baxter Healthcare | $97.92 | 2022-2025 | Hillrom - Volara System, Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Enterprises LLC | $70.37 | 2019 | |
| Ani Pharmaceuticals, INC. | $56.79 | 2025 | Purified Cortrophin Gel |
| Shire North American Group INC | $44.17 | 2019 | |
| Gilead Sciences, INC. | $43.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.62 | 2021-2022 | |
| Viatris Specialty LLC | $30.12 | 2025 | Yupelri |
| Alcresta Therapeutics, INC. | $24.92 | 2025 | Relizorb |
| Pinnacle Biologics, INC | $24.10 | 2024 | Photofrin |
| Pulmonx Corporation | $23.93 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Pfizer INC. | $19.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.34 | 2019 | |
| Pharming Healthcare, INC. | $14.75 | 2024 | Ruconest |
| Fisher & Paykel Healthcare INC | $13.03 | 2019 | |
| Advanced Respiratory, INC | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rumi Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.